Opendata, web and dolomites

BETTER-B SIGNED

BETTER TREATMENTS FOR BREATHLESSNESS IN PALLIATIVE AND END OF LIFE CARE

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BETTER-B project word cloud

Explore the words cloud of the BETTER-B project. It provides you a very rough idea of what is the project "BETTER-B" about.

friends    patients    community    disciplinary    persists    health    clinician    trialists    unites    chronic    morbidity    trial    cb    obstructive    time    frightening    groups    life    placebo    breathlessness    purpose    recruits    medicines    services    treatment    clinical    18    detrimental    feasibility    tests    uk    underlying    society    antidepressant    wellbeing    accessible    randomised    respiratory    scientists    distresses    carers    reduce    guidance    blind    clinicians    reviews    psychosocial    versus    conduct    patient    physical    ireland    symptom    italy    suggest    ensures    interstitial    quality    324    caregivers    survey    medicine    family    economists    germany    palliative    care    licenced    sustained    lung    offers    copd    disease    alongside    despite    internationally    treating    world    operation    rehabilitation    ild    needing    widest    optimal    double    emergency    mirtazapine    group    refractory    poland    pulmonary    statisticians    months    geriatric   

Project "BETTER-B" data sheet

The following table provides information about the project.

Coordinator
KING'S COLLEGE LONDON 

Organization address
address: STRAND
city: LONDON
postcode: WC2R 2LS
website: www.kcl.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 3˙791˙503 €
 EC max contribution 3˙769˙999 € (99%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2018-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2022-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KING'S COLLEGE LONDON UK (LONDON) coordinator 1˙395˙122.00
2    UNIVERSITY OF LEEDS UK (LEEDS) participant 669˙111.00
3    UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN IE (DUBLIN) participant 476˙203.00
4    AZIENDA UNITA SANITARIA LOCALE DI REGGIO EMILIA IT (REGGIO EMILIA) participant 283˙960.00
5    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 230˙812.00
6    KLINIKUM DER UNIVERSITAET ZU KOELN DE (KOELN) participant 170˙383.00
7    THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN IE (DUBLIN) participant 109˙671.00
8    THE UNIVERSITY OF NOTTINGHAM UK (NOTTINGHAM) participant 106˙095.00
9    GDANSKI UNIWERSYTET MEDYCZNY PL (GDANSK) participant 97˙612.00
10    UNIVERSITA CATTOLICA DEL SACRO CUORE IT (MILANO) participant 88˙987.00
11    UNIWERSYTET MIKOLAJA KOPERNIKA W TORUNIU PL (TORUN) participant 76˙290.00
12    EUROPEAN RESPIRATORY SOCIETY CH (LAUSANNE) participant 65˙750.00
13    UNIVERSITY OF TECHNOLOGY SYDNEY AU (SYDNEY) participant 0.00

Map

 Project objective

The BETTER-B consortium tests whether mirtazapine, currently used as an antidepressant, is an effective treatment to reduce chronic or refractory breathlessness (CB) in patients with advanced chronic obstructive pulmonary or interstitial lung disease (COPD or ILD) needing palliative care or at the end of life.

Our focus is on breathlessness that persists despite optimal treatment of the underlying condition. This widespread and frightening symptom has a major detrimental impact on patients’ quality of life and distresses their family, friends and carers. It is associated with physical and psychosocial morbidity and results in high use of health care services, including emergency care.

There are no licenced medicines for CB in the world. It is a major challenge to clinical management, care quality and patient wellbeing. We have completed a feasibility trial in 60 patients, reviews and case studies that suggest mirtazapine is a promising treatment.

To assess if mirtazapine is effective, we conduct a randomised double blind clinical trial of mirtazapine versus placebo in patients with CB and COPD or ILD. The trial recruits 324 patients over 18 months across respiratory, palliative care and community services in Poland, Ireland, Italy, Germany and the UK. We study the effects of treatment over time on patients, their family or caregivers and care costs. We survey clinicians and produce accessible European guidance on treating CB.

The consortium unites a unique multi-disciplinary group of clinician scientists from respiratory, palliative, geriatric and rehabilitation fields, alongside statisticians, trialists, health economists, health care researchers, patient and consumer groups and a European Society. This ensures the optimal design and operation of the trial and the widest impact from its results.

Using an existing medicine for a different purpose offers a highly cost-effective approach for treatment that can be implemented and sustained internationally.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BETTER-B" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BETTER-B" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

RESHAPE (2019)

Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches – from Advanced Technology Developments to First-in-Human Trials

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More